Literature DB >> 20363245

Behavioural effects and regulation of PKCalpha and MAPK by huprine X in middle aged mice.

M Ratia1, L Giménez-Llort, P Camps, D Muñoz-Torrero, M V Clos, A Badia.   

Abstract

The behavioural effects of huprine X, a new anticholinesterasic inhibitor, as well as its effects on the regulation of protein kinase C (PKC), mitogen activated protein kinase (MAPK) and alpha-secretase (ADAM10 and TACE/ADAM17) related to amyloid precursor protein (APP) processing remain to be established. In the present work, 12 month old 126/SvxC57b/6 male mice which received chronic i.p. treatment with either saline, huprine X (0.04 micromol kg(-1) or huprine X (0.12 micromol kg(-1), were submitted to a battery of behavioural tests and thereafter the brains were dissected to study the neurochemical effects induced by huprine X. The results show that, in a dose dependent manner, huprine X facilitates learning and memory in the Morris water maze and improves some indicators of emotionality without inducing adverse effects, affecting motor activity nor anxiety-like behaviours, as measured in the open-field and corner tests. Moreover activation of downstream PKC/MAPK signaling pathways may underly these behavioural effects as well as the stimulation of the non-amyloidogenic processing of APP. Results obtained herein using a sample of aged animals strongly suggest that huprine X constitutes a promising therapeutic agent for the treatment of cholinergic dysfunction underlying aging and/or dementias. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20363245     DOI: 10.1016/j.pbb.2010.03.013

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  7 in total

1.  Early intervention in the 3xTg-AD mice with an amyloid β-antibody fragment ameliorates first hallmarks of Alzheimer disease.

Authors:  Lydia Giménez-Llort; Geovanny Rivera-Hernández; Marta Marin-Argany; José L Sánchez-Quesada; Sandra Villegas
Journal:  MAbs       Date:  2013-06-20       Impact factor: 5.857

2.  Tacrine(10)-hupyridone, a dual-binding acetylcholinesterase inhibitor, potently attenuates scopolamine-induced impairments of cognition in mice.

Authors:  Huixin Chen; Siying Xiang; Ling Huang; Jiajia Lin; Shengquan Hu; Shing-Hung Mak; Chuang Wang; Qinwen Wang; Wei Cui; Yifan Han
Journal:  Metab Brain Dis       Date:  2018-03-21       Impact factor: 3.584

3.  Huprines as a new family of dual acting trypanocidal-antiplasmodial agents.

Authors:  Julien Defaux; Marta Sala; Xavier Formosa; Carles Galdeano; Martin C Taylor; Waleed A A Alobaid; John M Kelly; Colin W Wright; Pelayo Camps; Diego Muñoz-Torrero
Journal:  Bioorg Med Chem       Date:  2011-01-21       Impact factor: 3.641

Review 4.  Emotion Processing Dysfunction in Alzheimer's Disease: An Overview of Behavioral Findings, Systems Neural Correlates, and Underlying Neural Biology.

Authors:  Shefali Chaudhary; Simon Zhornitsky; Herta H Chao; Christopher H van Dyck; Chiang-Shan R Li
Journal:  Am J Alzheimers Dis Other Demen       Date:  2022 Jan-Dec       Impact factor: 2.632

5.  The PKC-β selective inhibitor, Enzastaurin, impairs memory in middle-aged rats.

Authors:  Mari N Willeman; Sarah E Mennenga; Ashley L Siniard; Jason J Corneveaux; Matt De Both; Lauren T Hewitt; Candy W S Tsang; Jason Caselli; B Blair Braden; Heather A Bimonte-Nelson; Matthew J Huentelman
Journal:  PLoS One       Date:  2018-06-05       Impact factor: 3.240

6.  Clock/Sleep-Dependent Learning and Memory in Male 3xTg-AD Mice at Advanced Disease Stages and Extrinsic Effects of Huprine X and the Novel Multitarget Agent AVCRI104P3.

Authors:  Lydia Giménez-Llort; Mikel Santana-Santana; Míriam Ratia; Belén Pérez; Pelayo Camps; Diego Muñoz-Torrero; Albert Badia; Maria Victòria Clos
Journal:  Brain Sci       Date:  2021-03-26

7.  Neuroprotective Effects of the Multitarget Agent AVCRI104P3 in Brain of Middle-Aged Mice.

Authors:  Julia Relat; Julio Come; Belen Perez; Pelayo Camps; Diego Muñoz-Torrero; Albert Badia; Lydia Gimenez-Llort; M Victòria Clos
Journal:  Int J Mol Sci       Date:  2018-09-04       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.